Published in Vaccine Weekly, April 10th, 2002
So is BioPort Corp., the Lansing, Michigan, company that now is the sole U.S. provider of the existing vaccine. BioPort has worked on a new anthrax vaccine for the past year. Other researchers began as early as 1997.
One of the potential competitors might be ready for human safety trials this summer, but all are likely years away from approval for use.
BioPort just this year received U.S. Food and Drug Administration approval for its renovated labs that make a relatively old, slow-acting vaccine against anthrax. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.